Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Ardelyx, Inc.

Ardelyx focuses on developing first-in-class medicines for patients with unmet medical needs, particularly in the areas of chronic kidney disease and irritable bowel syndrome.

msh id	COM:ARDELYX
symbol	ARDX
name	Ardelyx, Inc.
homepage url	https://www.ardelyx.com
country	US
sector	Healthcare
industry	Biotechnology
market	STOCKS
employee count	267
crunchbase url	-
linkedin url	-
founders	-

market cap	1.3B
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.62
growth cost of revenue	3.32
growth depreciation and amortization	-0.21
growth ebitda	0.11
growth ebitda ratio	0.63
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-1
growth gross profit	1.22
growth gross profit ratio	-0.07

COM:ARDELYX

Ardelyx

Last Close

4.92

21/11 21:00

Market Cap

1.30B

Beta: -

Volume Today

3.72M

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	187.73M
cost of revenue	187.73M
depreciation and amortization	1.29M
ebitda	-55.35M
ebitda ratio	-0.44
eps	-0.3
eps diluted	-0.3
operating expenses	169.94M
operating income	-63.28M
operating income ratio	-0.51

accounts receivables	-14.3M
capital expenditure	-344K
cash at beginning of period	96.14M
cash at end of period	21.47M
inventory	12.45M
working capital ttm	197.69M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-